Cidara TherapeuticsCDTX
CDTX
About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Employees: 73
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
15% more funds holding
Funds holding: 40 [Q4 2024] → 46 (+6) [Q1 2025]
12% more capital invested
Capital invested by funds: $184M [Q4 2024] → $206M (+$22.3M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
10.2% less ownership
Funds ownership: 97.5% [Q4 2024] → 87.3% (-10.2%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
31%
downside
Avg. target
$56
10%
upside
High target
$75
48%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Roy Buchanan | 17%upside $59 | Market Outperform Maintained | 30 Jun 2025 |
RBC Capital Brian Abrahams | 48%upside $75 | Outperform Maintained | 24 Jun 2025 |
Guggenheim Seamus Fernandez | 35%upside $68 | Buy Maintained | 24 Jun 2025 |
HC Wainwright & Co. Joseph Pantginis | 5%upside $53 | Buy Maintained | 24 Jun 2025 |
WBB Securities Steve Brozak | 11%downside $45 | Strong Buy Reiterated | 23 Jun 2025 |
Financial journalist opinion
Based on 11 articles about CDTX published over the past 30 days
Neutral
Business Wire
4 days ago
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics
MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults and met both its primary and secondary efficacy endpoints, showing t.
Neutral
GlobeNewsWire
1 week ago
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
Positive
MarketBeat
1 week ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Neutral
GlobeNewsWire
1 week ago
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000 ® and Russell 3000 ® Indexes.
Neutral
GlobeNewsWire
2 weeks ago
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.
Positive
Seeking Alpha
2 weeks ago
Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy
Cidara Therapeutics' main value driver, CD388, recently achieved an impressive 76% protection in its Phase 2b trials. It also showed a compelling safety profile. In my view, CD388 now has a clear pathway to start its pivotal Phase 3 initiation relatively soon. CDTX raised roughly $250 million through stock. While this is relatively dilutive, the resulting valuation multiples still seem reasonable for new investors.
Neutral
GlobeNewsWire
2 weeks ago
Cidara Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara.
Neutral
GlobeNewsWire
2 weeks ago
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
Positive
Investors Business Daily
2 weeks ago
Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality
Cidara Therapeutics stock skyrocketed more than 90% on Monday after the company presented a promising update for its universal flu shot.
Positive
Benzinga
2 weeks ago
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
Cidara Therapeutics, Inc. CDTX stock is trading over 90% higher on Monday with a session volume of 3.2 million compared to the average volume of 181.7K.
Charts implemented using Lightweight Charts™